[ad_1]
Photo: Dado Ruvic, Reuters.
Due to problems with access to components, the promising Pfizer vaccine will deliver only half of its planned vaccine doses this year, the Wall Street Journal reports.
The case is being updated.
There is a company spokesperson reporting on the delay, according to the newspaper.
– It took longer than planned to update the supply of components, says the woman, whose name is not mentioned.
The reason is that the components previously used in production do not meet the requirements, says another source with knowledge of the production.
– We fixed it, but we ran out of time in regards to the delivery scheduled for this year.
Initially, the plan was to administer 100 million doses of vaccines this year, but now it has been reduced to 50 million.
also read
Also read: With these boxes, the Pfizer vaccine can be shipped to Norway
The EU has an agreement for 300 million doses
The vaccine, which is being developed by Pfizer and BioNTech, was approved by the UK on Wednesday and, according to the country’s Health Minister, will be used next week. They have an agreement to buy 40 million doses, enough to vaccinate 20 million people, since the vaccine will be administered in two doses.
This vaccine is also in the approval process in the EU and Norway, and a decision can be made before December 29. Preliminary test results show, according to Pfizer, that the vaccine is 95 percent effective and has no serious side effects. The EU alliance has signed an agreement to buy 300 million doses from EU countries and Norway.
Follow the development of the vaccine and see which candidates are relevant for Norway at VG vaccine overview here.
This summary shows the candidates who have applied for approval in the EU and therefore also in Norway:
